# Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

> **NCT01285388** · PHASE1 · COMPLETED · sponsor: **Yungjin Pharm. Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Metabolic Syndrome
- Obesity

## Interventions

- **DRUG:** MB12066

## Key facts

- **NCT ID:** NCT01285388
- **Lead sponsor:** Yungjin Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285388, "Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01285388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*